GlassScriptPhysician profile
Douglas A Dreher
NPI 1285604355
$4,505.50
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $351 · 2021: $227 · 2022: $75.28 · 2023: $246 · 2024: $2,986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,496 · Food and Beverage: $660 · Travel and Lodging: $75.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,496.00 |
| Food and Beverage | $660.05 |
| Travel and Lodging | $75.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,667.12 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $298.96 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $262.16 | 2019-2024 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.87 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $216.62 | 2019-2024 | Wegovy |
| Merck Sharp & Dohme LLC | $168.13 | 2019-2020 | |
| Abbvie INC. | $89.56 | 2021-2024 | |
| Amarin Pharma, INC. | $87.16 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $83.87 | 2021-2023 | |
| Glaxosmithkline, LLC. | $67.29 | 2019-2023 | Arexvy, Shingrix |
| Amgen INC. | $43.94 | 2020-2021 | |
| Exact Sciences Corporation | $35.60 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $32.28 | 2020 | |
| Boston Scientific Corporation | $30.41 | 2024 | Watchman Access System |
| Pfizer INC. | $27.00 | 2019-2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.77 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $20.22 | 2019 | |
| Gilead Sciences, INC. | $18.33 | 2020 | |
| Abbott Laboratories | $17.10 | 2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $17.07 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.98 | 2024 | |
| Idorsia Pharmaceuticals US INC | $16.88 | 2024 | Quviviq |
| Sanofi Pasteur INC. | $11.97 | 2019 | |
| Allergan, INC. | $6.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Dreher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.